Tyra raises $50M series A for cancer drug resistance

Tyra Biosciences emerged from stealth with a $50 million series A round to bring its first therapy to the clinic for drug-resistant cancer.

Alta Partners, RA Capital Management, Boxer Capital of

Read the full 306 word article

How to gain access

Continue reading with a
two-week free trial.